Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

Molecular Cancer Therapeutics

Volumn 13, Issue 2, 2014, Pages 364-374

  Campbell, Robert M ^a   Anderson, Bryan D ^a   Brooks, Nathan A ^a   Brooks, Harold B ^a   Chan, Edward M ^a   De Dios, Alfonso ^a   Gilmour, Raymond ^a   Graff, Jeremy R ^a   Jambrina, Enrique ^a   Mader, Mary ^b   McCann, Denis ^a   Na, Songqing ^a   Parsons, Stephen H ^a   Pratt, Susan E ^a   Shih, Chuan ^a,c   Stancato, Louis F ^a   Starling, James J ^a   Tate, Courtney ^a   Velasco, Juan A ^a   Wang, Yong ^b   Ye, Xiang S ^a   more..

^a ELI LILLY AND COMPANY   (United States)

^b ELI LILLY AND COMPANY   (Spain)

^c NONE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANISOMYCIN; CYTOKINE; IMIDAZOLE DERIVATIVE; LY2228820; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRIDINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL CULTURE; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENETICS; HELA CELL LINE; HUMAN; MACROPHAGE; MELANOMA, EXPERIMENTAL; METABOLISM; MOUSE; NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TREATMENT OUTCOME; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANISOMYCIN; BINDING SITES; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HUMANS; IMIDAZOLES; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MOLECULAR STRUCTURE; NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; RNA INTERFERENCE; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894215146     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0513     Document Type: Article

References (47)

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298:1912-34
2. Schultz RM. Potential of p38 MAP kinase inhibitors in the treatment of cancer. Prog Drug Res 2003;60:59-92
3. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 2003;17:1969-78
4. Sandler H, Stoecklin G. Control of mRNA decay by phosphorylation of tristetraprolin. Biochem Soc Trans 2008;36:491-6
5. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537-49
6. Tate C, Blosser W, Wyss L, Evans G, Xue Q, Pan Y, et al. LY2228820 dimesylate, a selective inhibitor of p38 mitogen-Activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo. J Biol Chem 2013;288:6743-53
7. Schieven GL. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem 2005;5:921-8
8. Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38 (MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 2009;15:369-79
9. del Barco Barrantes I, Nebreda AR. Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans 2012;40:79-84
10. Benedetti V, Perego P, Luca Beretta G, Corna E, Tinelli S, Righetti SC, et al. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol Cancer Ther 2008;7:679-87
11. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8
12. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44
13. Campbell RM, Xin X, Xia X, Ye X, Lee P, Schultz RM, et al. Effect of a selective p38-MAPK inhibitor (LY479754) on the tumor microenvironment: implication of macrophage-derived p38-MAPK in the growth of murine P815 mastocytoma tumors. Proc Am Assoc Cancer Res 2005; 46 (suppl, abstr 2609).
14. Moscova M, Marsh DJ, Baxter RC. Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines. Cancer Res 2006;66:1376-83
15. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev 2006;17:325-37
16. Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA, et al. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1b. J Biol Chem 2010;285:6477-88
17. Peng HH, Liang S, Henderson AJ, Dong C. Regulation of interleukin-8 expression in melanoma-stimulated neutrophil inflammatory response. Exp Cell Res 2007;313:551-9
18. Dong C, Slattery MJ, Liang S, Peng HH. Melanoma cell extravasation under flow conditions is modulated by leukocytes and endogenously produced interleukin 8. Mol Cell Biomech 2005;2:145-59
19. Fimmel S, Devermann L, Herrmann A, Zouboulis C. GRO-A: a potential marker for cancer and aging silenced by RNA interference. Ann N Y Acad Sci 2007;1119:176-89
20. von Felbert V, Cordoba F, Weissenberger J, Vallan C, Kato M, Nakashima I, et al. Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma. Am J Pathol 2005;166:831-41
21. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, et al. The inflammatory cytokine tumor necrosis factor-A generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007;67:585-92
22. Suswam E, Li Y, Zhang X, Gillespie GY, Li X, Shacka JJ, et al. Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells. Cancer Res 2008;68:674-82
23. Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, et al. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-Activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. Br J Haematol 2007;136:414-23
24. Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, et al. p38 mitogen-Activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol 2008;141: 598-606
25. Hideshima T, PodarK, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 2004;23:8766-76
26. Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003;101:703-5
27. He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, et al. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res 2012;72:6393-402
28. Gaundar SS, Bradstock KF, Bendall LJ. p38MAPK inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stromamediated proliferation of acute lymphoblastic leukemia cells. Cell Cycle 2009;8:2975-83
29. ZhuYM,Webster SJ, Flower D,Woll PJ. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer 2004;91:1970-6
30. Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer 2007; 56:25-33
31. Yuan A, Chen JJ, Yao PL, Yang PC. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 2005;10:853-65
32. Kuwahara I, Lillehoj EP, Lu W, Singh IS, Isohama Y, Miyata T, et al. Neutrophil elastase induces IL-8 gene transcription and protein release through p38/NF-kB activation via EGFR transactivation in a lung epithelial cell line. Am J Physiol Lung Cell Mol Physiol 2006;291:L407-16
33. Walter M, Liang S, Ghosh S, Hornsby PJ, Li R. Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 2009;28:2745-55
34. Neininger A, Kontoyiannis D, Kotlyarov A, Winzen R, Eckert R, Volk HD, et al. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different posttranscriptional levels. J Biol Chem 2002;277:3065-8
35. Zhao F, Falk C, Osen W, Kato M, Schadendorf D, Umansky V. Activation of p38 mitogen-Activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res 2009;15:4382-90
36. WangS, Yang J, Qian J,Wezeman M, Kwak LW, Yi Q. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 2006;107: 2432-9
37. Merck Millipore KinaseProfiler Service Assay Protocols v62. Available from: http://www.millipore.com/techpublications/tech1/pf3036 [Accessed Dec. 30, 2013].
38. de Dios A, Shih C, Lopez de Uralde B, Sanchez C, del Prado M, Martin Cabrejas LM, et al. Design of potent and selective 2-Aminobenzimidazole-based p38a MAP kinase inhibitors with excellent in vivo efficacy. J Med Chem 2005;48:2270-3
39. Mader M, de Dios A, Shih C, Bonjouklian R, Li T, White W, et al. Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38a MAP kinase inhibitors with excellent in vivo antiinflammatory properties. Bioorg Med Chem Lett 2008;;18:179-83
40. Crohns M, Saarelainen S, Laine S, Poussa T, Alho H, Kellokumpu-Lehtinen P. Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy -Association of interleukin-8 and VEGF with survival. Cytokine 2010;50:30-6
41. Greenberg AK, Basu S, Hu J, Yie TA, Tchou-Wong KM, Rom WN, et al. Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol 2002;26:558-64
42. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, et al. Prognostic significance of phosphorylated P38 mitogen-Activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 2004;100:499-506
43. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, et al. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 2001;7:171-7
44. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-Activated protein kinase. J Clin Oncol 2005;23:2469-76
45. Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, Linderholm B. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res 2008;6:1630-8
46. Shi YY, Small GW, Orlowski RZ. Proteasome inhibitors induce a p38 mitogen-Activated protein kinase (MAPK)-dependent anti-Apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 2006;100:33-47
47. Goetz MP, Tolcher AW, Haluska P, Papadopoulos KP, Erlichman C, Beeram M, et al. A first-in-human phase I study of the oral p38 MAPK inhibitor LY2228820 dimesylate in patients with advanced cancer. J Clin Oncol 2012;30 (suppl):abstract 3001.